Associated Papers
Unleashed condensation by recurrent mutations of an epigenetic regulator promotes cancer.
Song Y et al.
Biorxiv : the Preprint Server for Biology, 2026
Philadelphia chromosome-positive de novo myelodysplastic syndrome with the p230 BCR::ABL1 fusion gene: a case report.
Kawai H et al.
International Journal of Hematology, 2026
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.
Kato T et al.
British Journal of Cancer, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab.
Khattri A et al.
Cancer Gene Therapy, 2024
A high proportion of germline variants in pediatric chronic myeloid leukemia.
Krumbholz M et al.
Molecular Cancer, 2024
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A et al.
Journal of Hematology & Oncology, 2024
Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia.
Ushijima Y et al.
Scientific Reports, 2024
Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.
Köhnke T et al.
Blood Cancer Discovery, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Kubota Y et al.
Nature Communications, 2024
A new genomic framework to categorize pediatric acute myeloid leukemia.
Umeda M et al.
Nature Genetics, 2024
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC et al.
International Journal of Hematology, 2023
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Luque Paz D et al.
Hemasphere, 2023
ASXL1/2 mutations and myeloid malignancies.
Medina EA et al.
Journal of Hematology & Oncology, 2022
Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia.
Umeda M et al.
Blood Cancer Discovery, 2022
Acquired somatic variants in inherited myeloid malignancies.
Armes H et al.
Leukemia, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.
Adnan Awad S et al.
Blood Cancer Journal, 2022
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.
Schmitt N et al.
Leukemia, 2022
Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia.
Mohanty S et al.
Cancers, 2021
Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia.
Fan Y et al.
Cancer Cell International, 2021
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
Simonetti G et al.
Leukemia, 2021
Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
Fang X et al.
Leukemia, 2021
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L et al.
Nature Cancer, 2021
Clonal hematopoiesis: Molecular basis and clinical relevance.
Kunimoto H et al.
Leukemia Research, 2020
ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C et al.
Cancer Medicine, 2020
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies.
Hendricks A et al.
Cancers, 2020
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.
von Loga K et al.
Nature Communications, 2020
SET Domain Containing 2 Deficiency in Myelodysplastic Syndrome.
Li J et al.
Frontiers in Genetics, 2020
The functional mechanisms of mutations in myelodysplastic syndrome.
Nagata Y et al.
Leukemia, 2019
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
Follo MY et al.
Leukemia, 2019
Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S et al.
International Journal of Hematology, 2019
The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
Uni M et al.
Leukemia, 2019
appreci8: a pipeline for precise variant calling integrating 8 tools.
Sandmann S et al.
Bioinformatics (oxford, England), 2018
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
Mei Z et al.
Bmc Cancer, 2018
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.
McKerrell T et al.
Blood, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
Merlevede J et al.
Nature Communications, 2016
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.
Kulasekararaj AG et al.
Blood, 2014